Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Regulus Therapeutics Skyrocketed Higher Today

By George Budwell - Feb 17, 2016 at 11:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma may have just hit pay dirt with its experimental hepatitis C treatment.

What: Shares of Regulus Therapeutics (RGLS 2.41%) gained as much as 41% in early morning trading on Wednesday after the company released positive interim results for its experimental hepatitis C treatment in an ongoing mid-stage study. Per the press release, this injected drug (known as RG-101) reportedly showed the ability to reduce the average treatment duration in patients taking all-oral medications such as Gilead Sciences (GILD 1.84%) Harvoni, Johnson & Johnson's (JNJ 0.29%) Olysio, or Bristol-Myers Squibb's (BMY -0.13%) Daklinza by a noteworthy eight weeks. 

So what: The next step in the evolution of so-called next-generation hepatitis C medications is to shorten the average treatment duration from 12 weeks to just four weeks across the varied landscape of patient populations. After today's clinical update, RG-101 appears to be a major step forward in this effort. 

Now what: Regulus is now planning on accelerating the development of RG-101 following these highly positive interim data. The burning question in shareholders' minds, though, is whether or not these results will catch the eye of a potential suitor for the company. After all, big pharma has been willing to pay top dollar for promising hepatitis C treatments in the past, and Regulus seems to have an important new drug on its hands. In short, it's not unreasonable to think that Bristol, Gilead, or J&J may consider acquiring Regulus after this latest clinical update for RG-101. Stay tuned. 

George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regulus Therapeutics Inc. Stock Quote
Regulus Therapeutics Inc.
$1.70 (2.41%) $0.04
Johnson & Johnson Stock Quote
Johnson & Johnson
$170.67 (0.29%) $0.49
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.14 (1.84%) $1.14
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.86 (-0.13%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.